{Reference Type}: Practice Guideline
{Title}: Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer.
{Author}: Yoshino T;Argilés G;Oki E;Martinelli E;Taniguchi H;Arnold D;Mishima S;Li Y;Smruti BK;Ahn JB;Faud I;Chee CE;Yeh KH;Lin PC;Chua C;Hasbullah HH;Lee MA;Sharma A;Sun Y;Curigliano G;Bando H;Lordick F;Yamanaka T;Tabernero J;Baba E;Cervantes A;Ohtsu A;Peters S;Ishioka C;Pentheroudakis G;
{Journal}: Ann Oncol
{Volume}: 32
{Issue}: 12
{Year}: 12 2021
{Factor}: 51.769
{DOI}: 10.1016/j.annonc.2021.08.1752
{Abstract}: The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (ISMPO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug availability and reimbursement situations in the different Asian countries.